Urolithin A is a compound your gut bacteria make from polyphenols in pomegranates, walnuts, and certain berries. It triggers mitophagy, the process by which your cells recycle old, damaged mitochondria and replace them with fresh ones. Mitochondrial quality declines from your 30s onward, and that decline is one of the main drivers of muscle weakness, slower recovery, fatigue, and visible aging. Most people take Urolithin A to slow that down.
The practical catch is that only around 40% of people have the right gut bacteria to convert dietary precursors into meaningful amounts of Urolithin A, and this conversion declines with age. Eating pomegranates does very little for the other 60%. Direct supplementation bypasses the microbiome entirely, which is why the clinical trials all use a standardised form rather than relying on diet. Effects are slow, you won't feel anything in week one, but human trials show measurable improvements in muscle endurance, strength, inflammation markers, and immune cell function over 2-4 months at 500-1000 mg daily.
Deep-dive
Mitochondria are the energy-producing organelles inside almost every cell, and their quality directly determines how well your tissues function. Damaged mitochondria don't just stop producing ATP efficiently, they leak reactive oxygen species, drive low-grade inflammation, and signal cellular stress. Healthy cells maintain quality through mitophagy, a selective form of autophagy where the cell tags damaged mitochondria with proteins like PINK1 and Parkin, then engulfs and degrades them. New mitochondria are made through biogenesis to replace the lost ones. The whole turnover system slows down with age, and damaged mitochondria accumulate.
Urolithin A activates mitophagy through both the PINK1/Parkin pathway and a Parkin-independent route. The mechanism is conserved from worms to humans, and in animal models it extends lifespan and improves muscle, brain, joint, and immune function. The question for humans was always whether the effect would translate, and over the last few years a series of randomised placebo-controlled trials have answered yes, at least for muscle and immune outcomes.
Muscle strength and endurance. The largest trial to date, a 4-month RCT in 88 middle-aged adults, showed roughly 12% improvements in hamstring and knee flexion strength at both 500 mg and 1000 mg doses, with the 1000 mg group also improving aerobic endurance and 6-minute walk distance. The primary endpoint of peak power output didn't reach significance. An earlier 4-month trial in 66 older adults found significant improvements in muscle endurance in the hand and tibialis anterior muscles, alongside drops in plasma C-reactive protein, acylcarnitines, and ceramides. An 8-week study in 20 resistance-trained young male athletes at 1 g/day showed gains in bench press 1RM, squat 1RM, and reps to failure, suggesting the effect isn't restricted to older or sedentary populations.
Immune function. A 2026 trial in 50 middle-aged adults gave 1 g/day for 4 weeks and found expansion of naive-like CD8+ T cells, increased CD8+ fatty acid oxidation capacity, more NK cells, and improved monocyte bacterial uptake. Translation: the immune system started looking younger and metabolically more flexible. This is the first evidence that Urolithin A directly targets the immune ageing process, and the time course (4 weeks) is much faster than the muscle adaptations.
Mitochondrial biomarkers. Across trials, Urolithin A consistently lowers plasma acylcarnitines (a sign of inefficient fatty acid oxidation, often elevated in mitochondrial dysfunction) and C-reactive protein. Skeletal muscle proteomics show upregulation of mitophagy and mitochondrial biogenesis proteins. The first-in-human Phase 1 trial demonstrated good bioavailability and a clear molecular signature of improved mitochondrial health.
Skin. Topical Urolithin A has been tested in three randomised trials, including post-menopausal women with visible wrinkles. Twice-daily application of 0.5-1% cream for 8 weeks reduced wrinkle depth, upregulated collagen genes, downregulated collagen-degrading enzymes, and protected against UVB-induced photodamage. Oral supplementation also seems to support skin via the same mitochondrial mechanism, but the topical evidence is more direct.
Limitations. The vast majority of human trials are funded by Amazentis, the company that makes Mitopure, the only standardised pharmaceutical-grade form on the market. The trials are well-designed, but independent replication is still limited. Long-term safety data beyond 4 months in humans doesn't exist. The effect size on muscle strength (around 12%) is real but modest, and trials in well-trained or already-active people are scarce. The aerobic endurance and walk-test improvements were labelled clinically meaningful but didn't always hit statistical primary endpoints. And while the compound activates mitophagy, a recent systematic review noted it didn't change maximal mitochondrial ATP production, biogenesis, or gut microbiota composition in human trials, suggesting the effect on mitochondrial output may be more about cleaning up dysfunction than boosting peak capacity.
Women. The pivotal muscle and immune trials enrolled women alongside men in roughly equal proportion, and the muscle strength gains in the 88-adult trial held across both sexes. Urolithin A has weak estrogen receptor binding activity but the doses required to act as a selective estrogen receptor modulator are higher than what's reached with normal supplementation, so it isn't really behaving as a phytoestrogen at standard doses. The bigger relevance for women is timing. Estrogen normally supports mitochondrial function and mitophagy directly, and when estrogen drops in perimenopause and after, the muscle mitophagy pathway suffers. Urolithin A activates mitophagy through PINK1/Parkin signalling that doesn't depend on estrogen, which makes it a logical fit for the menopause transition. Animal models of ovariectomy-induced bone loss show Urolithin A reduces osteoclast activity and protects bone density, but this hasn't been tested in postmenopausal women yet. Skip during pregnancy and breastfeeding, no safety data.
Older adults. This is the demographic with the most to gain. The 4-month older adult trial ran in adults aged 65-90 and showed clear endurance improvements at 1 g/day with no safety signals. Mitochondrial dysfunction accumulates significantly with age and the proportion of natural urolithin producers drops. If you're over 60 and not eating pomegranates and walnuts daily, you're almost certainly not making meaningful amounts.
Dosage:
- Standard dose: 500 mg/day for general healthspan and muscle support, taken any time of day with or without food. This is the most studied dose and the one with the cleanest cost-benefit ratio
- Higher dose: 1000 mg/day if you're specifically targeting muscle endurance, immune function, or are over 60. The 1 g dose has shown stronger effects on aerobic endurance and immune cell remodelling than 500 mg in head-to-head trials. The 8-week resistance training trial in young athletes also used 1 g
- Don't exceed 1000 mg/day. No clinical benefit has been shown above this and long-term safety data above this dose doesn't exist
- Timing: Daily and consistent. Effects build slowly. Mitochondrial gene expression changes appear by 4 weeks, immune cell shifts at 4 weeks, muscle endurance improvements at 2 months, peak strength gains at 4 months. Skipping doses defeats the purpose
- With or without food: Doesn't significantly matter, bioavailability is solid either way. If GI upset occurs, take with food
- Forms: Mitopure (the branded form from Amazentis) is the only product used in essentially every human clinical trial. Generic Urolithin A from other manufacturers may be chemically identical but isn't the same product, and purity and bioavailability vary widely. If you want the dose used in research, this is the only validated source. The compound is hard to manufacture cleanly which is why prices are high
- Diet alone won't get you there. A glass of pomegranate juice produces around six times less plasma Urolithin A than a 500 mg supplement, and only if you're a producer. Eating walnuts, pomegranates, and berries is good for you for many other reasons but isn't a reliable strategy for this specific compound
- Stacking: Pairs naturally with creatine and protein for muscle, and with exercise itself, which is the most potent endogenous mitophagy activator. No documented negative interactions with common supplements. Avoid stacking with high-dose pomegranate extracts, you're already targeting the same pathway
Here's what you can expect:
Nothing dramatic in the short term. Urolithin A doesn't have an acute subjective effect, you don't feel it the way you'd feel caffeine or creatine. The benefits are measured in changes to underlying biology, not in how you feel after a dose.
In the first month, the changes happening are at the cellular level, mitophagy gene expression shifts, and immune cell remodelling. You won't notice these directly. Some people report slightly better exercise recovery and reduced soreness around 4-8 weeks, which is consistent with the anti-inflammatory mechanism but is subjective.
By 2-4 months, the measurable functional changes start to emerge. In trials, muscle endurance improvements showed up first (around 2 months), with strength gains and walk-test improvements landing at 4 months. Plasma inflammation markers and acylcarnitines drop in this window. If you're going to notice anything subjectively, it'll be in this period, and it tends to be things like training feeling slightly easier, recovery being faster, or general energy being a bit more consistent.
If you stop taking it, the underlying mitophagy benefits will fade as cellular turnover slows back down. This is a compound you take consistently or not at all. It also can't replace exercise. The biggest mitophagy activator known is hard physical training, and Urolithin A complements that rather than substitutes for it. Sedentary people on Urolithin A still benefit, but the combination of training plus supplementation is where the effect sizes get largest.
Side effects & risks:
- Very well tolerated overall. Across 25+ human clinical trials in over 250 healthy adults, no serious adverse events have been linked to Urolithin A. The most-reported mild side effect is occasional muscle aches (myalgia), classified as possibly related. Headaches, mild GI discomfort, and back or limb stiffness have been reported at low rates and were typically not attributed to the supplement
- No effect on liver, kidney, or heart markers at doses up to 1000 mg/day for 4 months in monitored trials. Liver enzymes, kidney function tests, blood lipids, and ECG parameters stayed within normal ranges
- GI symptoms like mild diarrhea or stomach discomfort can occur, particularly when starting. Usually transient. Take with food if it happens
- Topical use has shown a few cases of mild skin irritation in the skincare trials, no other concerns
- Long-term human safety data is limited. The longest well-controlled trials have run 4 months. Beyond that, human data is sparse. Animal toxicology studies established a No Observed Adverse Effect Level of around 3,500 mg/kg/day, which translates to a comfortable safety margin at human supplemental doses, but multi-year human data simply doesn't exist yet
- Drug interactions are not formally established. Pomegranate juice (a precursor source) is known to interact with cytochrome P450 enzymes and may affect metabolism of certain medications, but pure Urolithin A doesn't appear to have the same interaction. If you're on cytochrome-sensitive medications (some statins, blood thinners, immunosuppressants), check with your prescriber
- Hormone-sensitive cancers. Urolithin A has weak estrogen receptor binding and acts as a SERM in some preclinical models. The data on whether this is meaningful at supplemental doses is mixed, and there's no evidence of harm in clinical trials, but if you have a history of estrogen-sensitive breast or endometrial cancer, discuss with your oncologist before using
- Pregnancy and breastfeeding. No safety data. Skip it
Blood markers
High-sensitivity C-reactive protein (hs-CRP), baseline if you can. Urolithin A consistently lowers CRP across trials, so this is the most likely marker to see move on standard bloodwork. Recheck at 3-4 months. If your baseline CRP is already low (under 1 mg/L), don't expect much room to drop.
Lipid panel and standard metabolic panel, baseline. Not because Urolithin A is expected to move these, but to rule out anything that might confound how you interpret changes in energy or recovery, and to confirm liver and kidney function at baseline if you're planning long-term use.
Plasma acylcarnitines, optional and only available through specialty metabolomics panels. These drop with Urolithin A use and are a reasonably direct readout of mitochondrial efficiency. Useful if you're tracking the mechanism, not necessary for most people.
Most people don't need any specific bloodwork to take Urolithin A. The compound is well-tolerated, the dose ceiling is low, and there are no organ markers that have shifted in trials.
Sold as a dietary supplement. FDA GRAS-notified in 2018.
Made with Bullet